Inh-172 Vaginal Non-Hormonal Contraceptive
Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Not Yet Determined
-
Intended Duration:
- Not Yet Determined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Oregon Health & Science University
Details
- API: Inh-172
- Target: Cystic Fibrosis Transmembrane Conductance Regulator
-
Mechanism of Action:
- Cervical Mucus Changes
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Developers indicate their intention to develop a user-controlled, non-hormonal, vaginal method. These attributes align with current data on user preference.
Product Status
Active/Recent Pre-Clinical Evaluation
History
2024: OHSU awarded NIH funding to pursue IND-enabling evaluation of novel API, Inh-172, as a non-hormonal vaginal contraceptive. Funding is renewed in 2025.